SLC10A1

Hepatic sodium/bile acid cotransporter · Q14973 · SLC10A1 on Sugi Atlas →

36,926 patent compounds predicted against SLC10A1, 25,466 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Taurochenodeoxycholate (SCHEMBL40763)	0.89	6/20
Taurursodiol (SCHEMBL40764)	0.89	6/20
Taurochenodeoxycholate (SCHEMBL56779)	0.89	6/20
Taurochenodeoxycholate (SCHEMBL56780)	0.89	6/20
Taurochenodeoxycholate (SCHEMBL287762)	0.89	6/20
Taurochenodeoxycholate (SCHEMBL288610)	0.86	6/20
SCHEMBL207597	0.64	6/20
SCHEMBL288289	0.69	4/20
Squalamine (SCHEMBL313361)	0.50	4/20
Taurocholic Acid (SCHEMBL3705)	1.00	3/20
Taurocholic Acid (SCHEMBL3706)	1.00	3/20
Taurocholic Acid (SCHEMBL435030)	1.00	3/20
Taurocholic Acid (SCHEMBL124237)	0.98	3/20
Taurocholic Acid (SCHEMBL205933)	0.97	3/20
Taurocholic Acid (SCHEMBL205934)	0.97	3/20
Taurochenodeoxycholate (SCHEMBL60947)	0.76	3/20
Taurochenodeoxycholate (SCHEMBL60964)	0.76	3/20
Taurochenodeoxycholate (SCHEMBL178108)	0.76	3/20
Taurocholic Acid (SCHEMBL207596)	0.73	3/20
SCHEMBL232878	0.66	3/20

Clinical trials — most relevant to SLC10A1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity	PHASE4	COMPLETED
Cholestatic Drug-induced Liver Injury	PHASE4	UNKNOWN
Effect of the Sequestrant Colesevelam in Bile Acid Diarrhoea	PHASE4	COMPLETED
BSEP Function Rescue During Childhood Inhereditary Cholestatic Diseases	PHASE2/PHASE3	WITHDRAWN
Obeticholic Acid Among Chronic HBV Patients with Hepatic Steatosis : Clinical and Portal Doppler Outcomes	PHASE3	NOT_YET_RECRUITING
Efficacy and Tolerability of Tauroursodeoxycholic Acid in Amyotrophic Lateral Sclerosis	PHASE2	COMPLETED
Secretin in Ex-situ Liver Perfusion	PHASE1/PHASE2	ENROLLING_BY_INVITATION
Comparative Study Between Obeticholic Acid Versus Vitamin E in Patients with Non-alcoholic Steatohepatitis	PHASE2	ACTIVE_NOT_RECRUITING
Effect of Non-Alcoholic Steatohepatitis (NASH) on the Pharmacokinetics of 99mTechnetium-Mebrofenin	PHASE1	COMPLETED
A Repeat Dose Study to Investigate the Interaction of GSK2190915 on the Pharmacokinetics of Rosuvastatin	PHASE1	COMPLETED
Drug-drug Interaction Study in Healthy Male Volunteers Following the Administration of Pantoprazole and Rosuvastatin	PHASE1	COMPLETED
Effect of, OAT3, on the Renal Secretion of Cefotaxime	PHASE1	COMPLETED
Drug-Drug Interaction of Rifampicin and Cyclosporine on Methotrexate Pharmacokinetics in Healthy Subjects	PHASE1	ACTIVE_NOT_RECRUITING
Effect of Obeticholic Acid on Transport of Bile Acids in PBC Examined by 11C-cholyl-sarcosine PET/CT	EARLY_PHASE1	COMPLETED
Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters	EARLY_PHASE1	COMPLETED
FGF19 in Obstructive Cholestasis: Unveil the Signal	nan	UNKNOWN
Regulation of Human Intestinal Bile Acid Transport in Health and Disease	nan	COMPLETED
PET/CT Scans Using the Tracer 11C-Csar, a Bile Acid Analog, to Depict and Visualize Cholestatic Disorders in Patients with Genetic Liver Disorders and Healthy Individuals	nan	ENROLLING_BY_INVITATION
Bile Acids Metabolism and Genetic Mutation Profile in the Intrahepatic Cholestasis of Pregnacy in Indian Population	nan	RECRUITING
ADPKD Alterations in Hepatic Transporter Function	nan	COMPLETED
Secondary Sclerosing Cholangitis in Critically Ill Patients	nan	ACTIVE_NOT_RECRUITING
Pediatric Evaluation and Registry for Liver Cholestasis in Canada	nan	RECRUITING
Role of Obeticholic Acid in the Patients of NAFLD With Raised ALT	nan	COMPLETED
The Role of Faecal Bile Acids in the Management of Bile Acid Diarrhoea	nan	COMPLETED
Utilizing Non-Invasive Fibroscan® Technology to Identify Genetic Markers for Fatty Liver Progression	nan	COMPLETED
Effects of Colesevelam HCl On Bile Acid Kinetics	nan	COMPLETED
Mechanisms of Glucose Lowering Effect of Colesevelam HCl	nan	COMPLETED
The Metabolic Profile in Intrahepatic Cholestasis of Pregnancy and Diabetes Mellitus	nan	COMPLETED
The Use of Fish Oil Supplementation in Treatment of Intrahepatic Cholestasis of Pregnancy	nan	WITHDRAWN
Gastrostomy-Biliary Diversion: Innovative Management for Bile Canalicular Transport Disorders	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a SLC10A1 binder may also engage these)

Protein	Name	Similarity
O08705	—	0.996	O08705 →
P26435	—	0.989	P26435 →
A6QP84	—	0.985	A6QP84 →
Q9CXB2	—	0.975	Q9CXB2 →
A2AWR3	—	0.975	A2AWR3 →
A2VCW5	—	0.974	A2VCW5 →
Q8C0X2	—	0.973	Q8C0X2 →
Q5EA97	—	0.973	Q5EA97 →
Q9C9K4	—	0.973	Q9C9K4 →
Q5SPB1	—	0.971	Q5SPB1 →
Q7Z3F1	—	0.970	Q7Z3F1 →
Q9DCP2	—	0.970	Q9DCP2 →
Q5R9A7	—	0.969	Q5R9A7 →
Q9SXJ8	—	0.968	Q9SXJ8 →
Q9SHL8	—	0.967	Q9SHL8 →
Q99624	—	0.967	Q99624 →
Q8WUX1	—	0.966	Q8WUX1 →
Q4JLT5	—	0.966	Q4JLT5 →
Q53P98	—	0.966	Q53P98 →
A8KBL5	—	0.966	A8KBL5 →
Q5PT54	—	0.965	Q5PT54 →
Q8K2P7	—	0.965	Q8K2P7 →
Q9UHW9	—	0.965	Q9UHW9 →
Q5PT55	—	0.965	Q5PT55 →
Q9H2H9	—	0.964	Q9H2H9 →
Q5F468	—	0.964	Q5F468 →
Q9JHZ9	—	0.964	Q9JHZ9 →
Q9FKY4	—	0.964	Q9FKY4 →
Q8R1S9	—	0.964	Q8R1S9 →
A1YG32	—	0.964	A1YG32 →